glp 1 updates Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1s are no longer the

Notably, Wegovy (semaglutide 2.4 mg) now has an additional indication for cardiovascular risk reduction in adults with established cardiovascular disease and either overweight or obesity

These are FDA's publicly stated consumer-protection areas of concern - not findings about any individual platform

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

Other signals suggest fragility: affordability barriers, side effects, and discontinuation patterns that may slow long-term momentum

AstraZeneca and Boehringer Ingelheim are developing next-gen compounds Ozmosi

These discrepancies may reflect species-specific differences that include the relative accessibility and importance of GLP-1R circuits in the CNS compared with those in the peripheral nervous system for controlling appetite, or these discrepancies may be due to other limitations, including the dose, potency, pharmacokinetics, and selectivity of the antagonist used and the short-term observation period